Abbvie Inc
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio.
Generated $14.7 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$208.84
-2.86%GoodMoat Value
$131.68
36.9% overvaluedAbbvie Inc (ABBV) YTD Return
Abbvie Inc — YTD Return
ABBV · NYSE · Healthcare
GoodMoat Target
“With a P/E ratio exceeding 85 against modest earnings, AbbVie's current valuation offers little margin of safety for the prudent value investor.”
— In the voice of Graham
What is the YTD Return?
Year-to-date total return including price appreciation. Compare performance against the S&P 500 benchmark.
Key Metrics
Market Cap
$369.10B
P/E Ratio
87.34
Forward P/E
—
EPS
$2.36
PEG Ratio
-0.01
Book Value
$-1.85
Dividend Yield
3.16%
Profit Margin
6.91%
ROE
—
YTD Return — Data
Pre-loaded data for ABBV:
Abbvie Inc (ABBV) YTD Return
Year-to-date total return including price appreciation. Compare performance against the S&P 500 benchmark.
Abbvie Inc is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. Current stock price: $208.84. Market capitalization: $369.10B. EPS: $2.36. P/E ratio: 87.34.
GoodMoat Fair Value target: $131.68. The stock appears 58.6% overvalued based on our blended model.
Use GoodMoat's YTD Return alongside other valuation tools including DCF Calculator, Reverse DCF, Fair Value models, and Quality Score to build a comprehensive investment thesis for Abbvie Inc (ABBV). All tools are free to use and powered by real-time financial data.